Revise study protocol: CDSCO Panels tells Lupin on Ranibizumab Solution for Injection 10 mg/mL Dr. Divya Colin30 April 2025 6:00 PM ISTNew Delhi: Responding to the drug major Lupin's proposal to conduct phase IV clinical trial of the ophthalmic drug Ranibizumab Solution for Injection...
BRESER Study Demonstrates Real-World Efficacy and Safety of Lupin's Ranibizumab Biosimilar (Ranieyes) Deeksha Bhandari11 April 2025 11:24 AM ISTRanieyes is the Ranibizumab Biosimilar which is an Indian Ranibizumab Biosimilar manufactured by Lupin Ltd & approved in India for various...
FDA approves ranibizumab for treating diabetic macular edema Dr. Kamal Kant Kohli5 Feb 2025 8:30 PM ISTThe U.S. Food and Drug Administration (FDA) has approved ranibizumab injection (Susvimo, 100 mg/mL; Genentech) for the treatment of diabetic macular...
Visual impairment due to macular oedema: Added benefit of faricimab not proven in new study Dr. Kamal Kant Kohli31 Dec 2024 10:30 PM ISTSince July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular oedema secondary to retinal vein...
Safety of Lupin's Ranibizumab (Ranieyes) established in Large-Scale Multicenter Study with 2194 injections in 1401 eyes MDTV Bureau6 Dec 2024 12:19 PM ISTReal-World Indian Data Confirms Safety of Lupin's Ranieyes for various Chorioretinal Vascular Disease Ranibizumab (Ranieyes) is a safe...
Sun Pharmaceutical Industries Gets CDSCO Panel Nod to Study Ranibizumab Solution for Injection Dr. Divya Colin9 Nov 2024 5:30 PM ISTNew Delhi: The drug major Sun Pharmaceutical Industries has got approval from the Subject Expert Committee (SEC) functional under the Central Drug...
Lupin completes Phase 3 trials for Lucentis biosimilar Ruchika Sharma6 Aug 2024 4:30 PM ISTMumbai: Global Pharma major Lupin Limited has announced the successful completion of a global Phase 3 clinical study of LUBT010, its biosimilar...
Stereotactic Radiotherapy Reduces Anti-VEGF Use in nAMD Without Affecting Visual Acuity: Study Dr Riya Dave19 Jun 2024 9:00 PM ISTResearchers have found that stereotactic radiotherapy (SRT) for neovascular age-related macular degeneration (nAMD) reduces the need for anti-vascular...
Incorporate sample size proportionate with each indication: CDSCO Panel Tells Sun Pharma on Ranibizumab study Dr. Divya Colin3 Jun 2024 6:00 PM ISTNew Delhi: Reviewing the proposal for conducting the Phase IV study of Ranibizumab Solution for Injection 10 mg/mL, the Subject Expert Committee (SEC)...
Sun Pharma Gets CDSCO Panel Nod for Additional Indication of Ranibizumab solution for injection Dr. Divya Colin16 Jan 2024 6:00 PM ISTNew Delhi: In line with the proposal presented by the drug major Sun Pharma, the Subject Expert Committee (SEC) functional under the Central Drug...
Lupin collaborate with Amman Pharma for marketing, commercialization of Ranibizumab in Middle East region Ruchika Sharma11 Nov 2023 10:00 AM ISTMumbai: Global Pharma major Lupin Limited has partnered with Amman Pharmaceuticals Industries, a pharmaceutical manufacturer with operations across...
Anti-VEGF combination therapy clinically effective treatment option for nAMD patients Aditi7 Jun 2023 8:00 PM ISTResearchers investigated the therapeutic efficacy and safety of OPT-302, a VEGF-C and VEGF-D biologic inhibitor, in combination with ranibizumab, a...
